The stock has declined 6.5% over 30 days and 8.9% year-to-date, prompting analysis on whether its current price offers value. The company recently reported earnings and announced a regular quarterly dividend. Despite recent weakness, some analysts label it a strong buy in healthcare. The focus is on whether the stock can rebound from its post-earnings drop and where it is headed next.